| Date | Title | Description | |
|---|---|---|---|
| 23 Feb 2022 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors | Download |
| 23 Feb 2022 | Annual Corporate Governance Report | ROVI releases the 2021 Annual Corporate Governance Report | Download |
| 21 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 | Download |
| 15 Feb 2022 | On business and financial situation | ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Download |
| 14 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Nov 2016 | Información sobre resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2016 results | Download |
| 08 Nov 2016 | Información sobre resultados (2) | ROVI releases the press release related to the nine-month period ended 30 September 2016 results | Download |
| 08 Nov 2016 | Otros sobre Gobierno Corporativo | The Company informs about the agreement of the Board of Directors with regards to the appointment of the Accounts Auditor | Download |
| 04 Oct 2016 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the third quarter of 2016 | Download |
| 01 Aug 2016 | Acuerdos estratégicos con terceros | ROVI announces the marketing agreement of Mysimba in Spain | Download |